German health care and science group Merck has sealed a deal to bolster its cancer treatment portfolio with a $3.9-billion ...

Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 billion, as the ...

Merck KGaA has reached an agreement with SpringWorks on a $47-per-share takeover deal that values the US biotech at $3.9 ...